Special Issue

Artificial Intelligence and Machine Learning in Precision Oncology

Message from the Guest Editors

Al is causing a paradigm shift in scientific research. In precision oncology, Al is reshaping the existing scenario, aiming to integrate and interpret large amounts of patients' data with current advances in high-performance computing and groundbreaking deep-learning strategies for better treatment decisions.

This special issue of Cancers is focused on the applications of AI/ML in precision oncology and cancer research. This include, but is not limited to, new AI/ML approaches for cancer detection, screening, diagnosis. and classification, as well as the characterization of the cancer genome, the analysis of tumor microenvironment, the evaluation of biomarkers for prognostic and predictive purposes, strategies for patient follow-up, and drug designing and development. In addition, new modes of interaction between patients and doctors using AI and avatars and the application of artificial intelligence in communication skills training are also welcome. We invite the research community to submit their latest and most significant research in the above-mentioned areas as original research articles, reviews, or short communications.

Guest Editors

Dr. Carmen Belli

Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy

Dr. Santosh Anand

Department of Biology, University of North Carolina Greensboro, Greensboro, NC, USA

Deadline for manuscript submissions

closed (30 April 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/138053

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

